First Trust Nasdaq BuyWrite Income ETF (NASDAQ: FTQI)

에 대한 최신 뉴스 First Trust Nasdaq BuyWrite Income ETF (NASDAQ:FTQI)

First Trust Nasdaq BuyWrite Income ETF

Technology

Consumer Cyclical

Communication Services

Healthcare

Financial Services

Industrials

Consumer Defensive

Energy

Real Estate

Basic Materials

Utilities

Other

The fund will pursue its objective by investing primarily in equity securities listed on U.S. exchanges and by utilizing an option strategy consisting of buying U.S. exchange-traded put options on the Standard & Poors 500 Index (the index) and writing (selling) U.S. exchange-traded covered call options on the index. The call options written by the fund will be a laddered portfolio of call options with expirations of less than one year, written at-the-money to slightly out-of-the-money. The fund is non-diversified.

Apple Inc

Microsoft Corp

Nvidia  Corporation 

Amazon.Com Inc

Broadcom, Inc. (purchase Right At $290.00 Per Share) (5)

Meta Platforms, Inc.

Costco Wholesale Corp.

Alphabet, Inc. (cl A)

Alphabet Class C

Netflix Inc Common Stock Usd 0.001

Tesla Inc. (usd)

T-Mobile Usa Inc Esrw Usd Npv Ref Sm#585558

Intuitive Surgical Inc

Nyc,ny - usa-may,27,2019:,Nasdaq,Sign,In,Times,Square,Nyc

FTQI

GOOG

GOOGL

MSFT

NVDA

QQQM

나스닥-100은 기술주가 끊임없는 상승을 이어가면서 화요일 사상 최고치인 22,191.37까지 급등했다. 이 지수를 추적하는 가장 인기 있는 ETF인 Invesco QQQ Trust(NASDAQ:QQQ)도 광범위한 기술 모멘텀을 반영하여 52주 최고가인 540달러를 경신했다.

나스닥-100이 사상 최고치를 기록하고 메타의 랠리가 기술주 급등을 주도

News

Movers

ASML

IRBO

SMCI

금요일 Arm 홀딩스(NASDAQ:ARM)의 주가는 엑산 BNP 파리바(Exane BNP Paribas)가 주식을 시장수익률 상회(Outperform)에서 중립(Neutral)으로 하향 조정한 후 금요일 급락했다. 상세 정보: 엑산 BNP 파리바의 분석가 데이비드 오코너(David O&#39;Connor)는 Arm을 시장수익률 상회(Outperform)에서 중립(Neutral)으로 하향 조정하고 주가 목표를 100달러로 발표했다.

ARM 홀딩스 주식은 이번 주 30% 이상 급락: 왜?

Barclays analyst Luke Sergott initiates coverage on West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) with a Equal-Weight rating and announces Price Target of $245.

Price Target

Initiation

Analyst Ratings

Barclays Initiates Coverage On West Pharmaceutical Servs with Equal-Weight Rating, Announces Price Target of $245

Wedbush analyst David Nierengarten reiterates argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) with a Outperform and maintains $715 price target.

Reiteration

ARGX

Wedbush Reiterates Outperform on argenx, Maintains $715 Price Target

Morgan Stanley analyst Toni Kaplan maintains FactSet Research Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) with a Underweight and raises the price target from $390 to $393.

Morgan Stanley Maintains Underweight on FactSet Research Systems, Raises Price Target to $393

For the full year 2025, the company expects:
<ul>
<li>Net yields (in constant currency) approximately 5.0 percent higher than strong 2024 levels, which were up 11 percent and 0.3 percentage points better than March guidance.</li>
<li>Adjusted cruise costs excluding fuel per ALBD (in constant currency) up approximately 3.6 percent compared to 2024, better than March guidance.</li>
<li>Adjusted net income up over 40 percent compared to 2024 and better than March guidance by $200 million.</li>
<li>Adjusted EBITDA of approximately $6.9 billion, up over 10 percent compared to 2024 and better than March guidance.</li>
</ul>

Carnival Corporation Sees FY25 Net Yields Approximately 5% Higher Than 2024 Levels, Which Were Up 11%

- Near doubling of 1-year overall survival (OS), increased median OS of 4 months (12.5 vs 8.5 months), and 43% reduction in risk of death in patients treated with at least one cycle (4 weeks) of elraglusib plus gemcitabine/nab-paclitaxel (GnP) vs GnP alone
- Patients with liver metastases experienced a 2.5x improvement in 1-year OS with a 38% reduction in risk of death when treated with elraglusib plus GnP
CHICAGO and FORT WORTH, Texas, June 24, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTU#NASDAQ">ACTU</a>) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today highlighted results from a pre-specified subgroup analysis of its Phase 2 (Actuate-1801 Part 3B) trial of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line metastatic pancreatic adenocarcinoma (mPDAC).
Patients treated for at least one complete cycle (4 weeks) of therapy achieved a median overall survival (mOS) of 12.5 months in the elragusib/GnP arm, compared to 8.5 months in the control arm. The analysis showed a 43% reduction in the risk of death relative to control, highlighting the significant potential impact of early disease control by elraglusib. Improved outcomes were reported in the combination versus control arms, respectively: disease control rate (DCR): 53.4% vs 44.8%, overall response rate (ORR): 37.9% vs 29.3%, and median progression-free survival (PFS): 6.9 vs 5.6 months.

ACTU

Actuate Therapeutics Highlights Results From Pre-Specified Subgroup Analysis Of Phase 2 Trial Of Elraglusib In Combination With GnP In First-Line Metastatic Pancreatic Adenocarcinoma

Study evaluates novel small molecule TNF-alpha inhibitor as potential alternative to biologic treatments
TNF Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it has formed a philanthropic collaboration with the DADA2 Foundation, a nonprofit organization seeking innovative ways to accelerate research into the rare inflammatory disease DADA2 (Deficiency of Adenosine Deaminase 2). Together, the parties are expected to initiate a Compassionate Use (Expanded Access) study evaluating TNF's lead candidate isomyosamine as a potential treatment.
The DADA2 Foundation describes DADA2 as a rare, monogenic recessively inherited autoinflammatory disease characterized by systemic inflammation, vasculitis, early-onset stroke, immunodeficiency, and bone marrow failure. The condition can lead to recurring childhood strokes at a young age and a high risk of premature death before adulthood. Early diagnosis is critical to minimize systemic organ damage.
TNF President and Chief Medical Officer, Mitchell Glass, M.D. commented, "The body of evidence surrounding DADA2 has shown that TNF inhibition is a most effective treatment for the hyperinflammatory and vasculitic aspects of this disease—a potentially fatal condition that primarily affects children. Compared with standard-of-care biological treatments, our TNF-alpha inhibitor, isomyosamine, is an orally administered small molecule with comparable potency, easier titration to the intended effect and, most importantly, anti-inflammatory action with minimal or no immunosuppression. We believe it could be a superior alternative for treating this devastating disease."
DADA2 Foundation Founder and President, Chip Chambers, M.D. commented, "Biological TNF inhibitors have shown to be the only safe and effective treatment for DADA2 patients with autoinflammatory/vasculitic forms of DADA2, but have many limitations including route of administration, cost, and the potential to lose efficacy over time. We are excited to explore isomyosamine as a potential new treatment to improve the lives of DADA2 patients and their families."
Approximately 25% of DADA2 patients are diagnosed before one year of age and 77% by 10 years of age. Patients who have bone marrow failure tend to present during early infancy, whereas delayed presentation is common in patients with vasculitis affecting medium- and small-sized vessels and systemic inflammation. There are more than 600 DADA2 patients today, but research suggests that 35,000 patients could be affected and undiagnosed globally.1

Biotech

General

TNFA

TNF Pharmaceuticals And DADA2 Foundation Launch Compassionate Use Study Of Oral TNF-Alpha Inhibitor Isomyosamine For Rare Pediatric Inflammatory Disease

Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>) with a Outperform and lowers the price target from $17 to $15.

Larimar Therapeutics, Inc. - Common Stock

LRMR

Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $15

Company also announces certain corporate actions
ROUND ROCK, TX / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 24, 2025 / AYRO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYRO#NASDAQ">AYRO</a>) ("AYRO" or the "Company"), today announces that it is exploring a range of strategic alternatives to enhance stockholder value, including digital asset initiatives, with a focus on the underlying technology of crypto-based stablecoins, and operational initiatives to grow its core business.
As part of this process, the Company is actively exploring new market opportunities that leverage its existing assets and balance sheet.
AYRO currently maintains a strong cash position of approximately $15.4 million, as of March 31, 2025, enabling significant flexibility to pursue strategic paths and support external opportunities.
"We continue to actively explore all strategic avenues to create value for our stockholders," said Josh Silverman, Executive Chairman of AYRO. "We believe our solid balance sheet enables us to pursue growth opportunities in emerging digital markets with a specific interest in technologies underlying stablecoins.
Reverse Stock Split
Additionally, the Company today announces that it intends to effect a reverse stock split of its common stock, par value $0.0001 per share (the "common stock") at a ratio of 1 post-split share for every 16 pre-split shares. The reverse stock split will become effective at 4:05 p.m. on Wednesday, June 25, 2025. The Company's common stock will continue to be traded on the Nasdaq Capital Market under the symbol AYRO and will begin trading on a split-adjusted basis when the market opens on Thursday, June 26, 2025. The new CUSIP number for the common stock following the reverse stock split is 054748306.
At the 2025 annual meeting of stockholders held on May 19, 2025, the Company's stockholders granted the Company's Board of Directors the discretion to effect a reverse stock split of the Company's common stock through an amendment to its Amended and Restated Certificate of Incorporation, as amended, at a ratio of not less than 1-for-2 and not more than 1-for-100, with such ratio to be determined by the Company's Board of Directors.
At the effective time of the reverse stock split, every sixteen (16) shares of the Company's issued and outstanding common stock will be converted automatically into one issued and outstanding share of common stock without any change in the par value per share. Stockholders holding shares through a brokerage account will have their shares automatically adjusted to reflect the 1-for-16 reverse stock split. It is not necessary for stockholders holding shares of the Company's common stock in certificated form to exchange their existing stock certificates for new stock certificates of the Company in connection with the reverse stock split, although stockholders may do so if they wish.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Stock Split

Markets

AYRO

AYRO Explores Strategic Alternatives Including Stablecoins; Announces 1-For-16 Reverse Stock Split, Will Begin Trading On A Split-Adjusted Basis When The Market Opens On Thursday, June 26, 2025

Morgan Stanley analyst Bob Huang maintains Voya Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOYA#NYSE">VOYA</a>) with a Overweight and raises the price target from $86 to $88.

VOYA

Morgan Stanley Maintains Overweight on Voya Financial, Raises Price Target to $88

SVCO

Silvaco Group Announces Strategic R&D Collaboration With Fraunhofer Institute For Silicon Technology To Accelerate Development Of Next-Gen GaN Devices Using Silvaco's Power Devices Solution To Perform DTCO

Uber Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) shares are moving higher Tuesday. The company announced that it began offering autonomous ride options with <a href="https://www.benzinga.com/markets/tech/25/06/46051889/teslas-4-20-robotaxi-disruption-waymo-should-be-worried">Waymo in Atlanta</a>.
What Happened: Uber on Tuesday said users in Atlanta can now be paired with a Waymo autonomous vehicle exclusively on the Uber app. 
Uber said riders will be able to travel across a 65 square mile area of Atlanta at launch, with plans to expand that range in the future. Riders in Atlanta may now be matched with a Waymo fully autonomous Jaguar I-PACE vehicle. Upon arrival, riders can unlock the doors and start the trip using the Uber app. 
Uber and Waymo <a href="https://www.benzinga.com/markets/equities/24/09/40855784/uber-stock-spikes-as-ceo-praises-waymos-fully-autonomous-trips">announced</a> an expanded partnership in September 2024 to bring autonomous ride options to Austin and Atlanta through the Uber platform. The Atlanta launch comes after the companies launched autonomous ride-hailing in Austin in March. 
Competition in the autonomous space is starting to heat up with Tesla&#8217;s official robotaxi <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46058796/tesla-stock-is-surging-today-whats-driving-the-momentum">launch</a> taking place over the weekend. Tesla officially launched robotaxi rides on Sunday through a &#8220;successful&#8221; invitation-only event, CEO Elon Musk <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46058796/tesla-stock-is-surging-today-whats-driving-the-momentum">said</a> on X.
Riders were charged a flat fee of $4.20 per ride, but it&#8217;s not clear what the pricing strategy will look like moving forward. Uber on Tuesday said its autonomous rides will be offered at no additional cost in Atlanta. 
&#8220;In&nbsp;<a href="https://investor.uber.com/news-events/news/press-release-details/2024/Uber-and-Waymo-Expand-Partnership-to-Bring-Autonomous-Ride-Hailing-to-Austin-and-Atlanta/default.aspx">Austin</a>, where Waymo rides are also exclusively available on Uber, there are now 100 Waymo vehicles on the platform, and that number is growing as the fleet scales across both Austin and Atlanta,&#8221; Uber said on Tuesday. 
UBER Price Action: <a href="http://benzinga.com/quote/uber">Uber shares</a> were up 3.12% at $87.90 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46069883/teslas-china-sales-slip-over-10-in-mid-june-after-strong-may-surge">Tesla&#8217;s China Sales Slip Over 10% in Mid-June After Strong May Surge</a></li>
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45967745/honeywell-near-earth-autonomy-test-pilot-free-helicopter-for-faster-safer-marine-supply">Honeywell, Near Earth Autonomy Test Pilot-Free Helicopter For Faster, Safer Marine Supply</a></li>
</ul>
Photo: Shutterstock.

UBER

Uber Stock Is Moving Higher Tuesday: What's Driving The Action?

Barclays analyst Luke Sergott initiates coverage on Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Overweight rating and announces Price Target of $150.

RGEN

Barclays Initiates Coverage On Repligen with Overweight Rating, Announces Price Target of $150

Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) shares climbed in premarket trading Tuesday after the company revealed a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n46071594/pepsico-leverages-salesforces-agentforce-to-advance-ai-agenda" rel="noreferrer noopener">significant collaboration</a> with PepsiCo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>), a move that appears to be boosting investor confidence.
The food and beverage giant plans to roll out Salesforce&#8217;s Agentforce platform, a tool designed to embed AI-driven digital agents directly into operational workflows to streamline customer and sales processes.
PepsiCo is among the first in its industry to integrate Agentforce at scale.
Also Read:<a target="_blank" href="https://www.benzinga.com/markets/tech/25/06/45989577/salesforce-raises-enterprise-software-prices-6-as-company-pushes-ai-powered-agentforce-platform" rel="noreferrer noopener"> Salesforce Raises Enterprise Software Prices 6% As Company Pushes AI-Powered Agentforce Platform</a>
The move is aimed at modernizing how sales and support teams operate, making them more agile and efficient in a data-driven environment.
According to Ramon Laguarta, Chairman and CEO of PepsiCo, the partnership underscores the company&#8217;s broader ambition to become more responsive and innovative by weaving AI into its everyday operations. With Agentforce, PepsiCo expects to elevate customer engagement and unlock insights that drive growth.
Through tools like Data Cloud, Consumer Goods Cloud, Service Cloud, and Marketing Cloud, Salesforce will help unify PepsiCo&#8217;s data streams and automate marketing and retail execution.
These platforms will enhance inventory visibility, facilitate real-time collaboration, and optimize promotions with AI-generated insights.
Beyond the consumer goods sector, Salesforce is also actively expanding its Agentforce platform into the healthcare industry, demonstrating the versatility and broad applicability of its AI-powered solutions.
In a separate press release, UChicago Medicine announced its adoption of Agentforce for Health, a tailored version of the platform, to support <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46071498/salesforce-collaborates-with-uchicago-medicine-to-enhance-patient-support" rel="noreferrer noopener">non-clinical patient services</a>.
By automating routine inquiries through AI-powered chat and phone agents, the hospital system aims to reduce staff workload while improving 24/7 access to key information.
Patients will soon be able to use self-service tools to handle appointment scheduling, insurance verification, and navigation support.
Andrew Chang, Chief Marketing Officer of UChicago Medicine, emphasized the platform&#8217;s potential to help staff focus on complex needs by offloading repetitive tasks to intelligent digital agents.
Salesforce&#8217;s latest developments highlight a broader trend of merging human expertise with autonomous systems to meet evolving operational demands across industries.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, CRM stock has gained over 9% in the past year. Investors can gain exposure to the stock via&nbsp;iShares Expanded Tech-Software Sector ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IGV#BATS">IGV</a>).
Price Action: CRM shares are trading higher by 1.11% to $266.34 premarket at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46069090/us-stocks-likely-to-open-higher-after-trump-announces-iran-israel-ceasefire-fedex-td-synnex-in-focus-ahead-of-earnings" target="_blank" rel="noreferrer noopener">US Stocks Likely To Open Higher After Trump Announces Iran-Israel Ceasefire: FedEx, TD Synnex In Focus Ahead Of Earnings</a></li>
</ul>
Photo by Erman Gunes via Shutterstock

Equities

Tech

PepsiCo Taps Salesforce To Deploy Agentforce For AI-Driven Growth

Houston American Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUSA#NYSE">HUSA</a>) (the "Company") today announced that it has entered into a definitive agreement with an institutional investor (the "SPA") for the purchase and sale of an aggregate of 81,629 shares of common stock at a purchase price of $14.80 per share in a registered direct offering (the "Offering").
The aggregate gross proceeds to the Company of this offering are expected to be approximately $1.2 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds of approximately $1 million from the offering for general corporate purposes. The transaction is expected to close on or about June 25, 2025, subject to the satisfaction of customary closing conditions.

Offerings

HUSA

Houston American Energy Announces $1.2M Registered Direct Offering Of 81,629 Shares Of Common Stock At $14.80 Per Share To Institutional Investor

Cantor Fitzgerald analyst Andres Sheppard maintains PureCycle Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) with a Overweight and raises the price target from $12 to $16.

Cantor Fitzgerald Maintains Overweight on PureCycle Technologies, Raises Price Target to $16

Fiserv Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) shares are trading higher Tuesday after Mastercard Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) announced plans to deepen its <a href="https://www.benzinga.com/pressreleases/25/06/b46069172/mastercard-partners-with-fiserv-to-accelerate-mainstream-stablecoin-adoption">partnership with the company</a>.
What Happened: Mastercard said it will integrate Fiserv&#8217;s new FIUSD token across a range of Mastercard products and services, bringing the blockchain-based token to over 150 million merchants. 
The companies plan to explore opportunities for stablecoin use including enabling FIUSD as a settlement option, leveraging Mastercard&#8217;s multi-token network and powering stablecoin-linked cards. 
&#8220;This work with Fiserv is setting the stage for a new era, where stablecoins are as ubiquitous and trusted as fiat currencies, driving choice and innovation for all,&#8221; said Chiro Aikat, co-president of the Americas at Mastercard. 
&#8220;Leveraging the power of the Mastercard network, as well as our deep capabilities across digital assets, we are creating a robust ecosystem that bridges traditional financial services with digital assets.&#8221;
See Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46055637/fiserv-paypal-expand-partnership-to-advance-stablecoin-payments">Fiserv, PayPal Expand Partnership To Advance Stablecoin Payments</a>
<h3 class="wp-block-heading">How To Buy FI Stock</h3>
By now you're likely curious about how to participate in the market for Fiserv &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
FI Price Action: <a href="http://benzinga.com/FI">Fiserv shares</a> were up 4.02% at $177.39 at the time off publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Fiserv Shares Are Trading Higher Tuesday: Here's Why

Strategic capital deployment into TAO advances Synaptogenix's blockchain treasury&nbsp;model, leveraging BitGo's custody, trading and staking capabilities to generate token-based yield
NEW YORK, June 24, 2025 /PRNewswire/ -- Synaptogenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPX#NASDAQ">SNPX</a>) today announced its initial purchase of TAO as part of the Company's recently announced cryptocurrency treasury strategy focused exclusively on artificial intelligence (Al) and machine learning. BitGo, the leading infrastructure provider of digital asset solutions, has been selected to provide qualified custody, staking and trading services for Synaptogenix's TAO holdings. BitGo brings unmatched expertise and a proven track record to help Synaptogenix implement its treasury strategy.
BitGo will secure Synaptogenix's digital assets in regulated, insured cold storage with BitGo Trust Company, Inc. and facilitate the Company's planned acquisitions of TAO through its affiliated trading platforms1, including access to deep liquidity via its OTC desk. TAO will be staked directly from qualified custody with BitGo Trust, enabling Synaptogenix to generate yield while maintaining the highest standards of security and regulatory compliance. BitGo's client service model and clients further reinforce its ability to meet Synaptogenix's unique digital asset needs. The Company has begun to generate revenue through TAO staking. The initial acquisition of TAO was funded by the Company's significant cash reserves and well-capitalized balance sheet.

SNPX

Synaptogenix Announces Initial Purchase Of TAO As Part Of Cryptocurrency Treasury Strategy Focused Exclusively On Al And Machine Learning; Selects BitGo As Custodian

<a href="https://truthsocial.com/@realDonaldTrump/posts/114738521695017472" title="https://truthsocial.com/@realDonaldTrump/posts/114738521695017472">https://truthsocial.com/@realDonaldTrump/posts/114738521695017472</a>

Macro Economic Events

Politics

Global

Economics

President Trump Posts On Truth Social "China can now continue to purchase Oil from Iran. Hopefully, they will be purchasing plenty from the U.S., also. It was my Great Honor to make this happen!"

Barclays analyst Luke Sergott initiates coverage on Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) with a Overweight rating and announces Price Target of $55.

QGEN

Barclays Initiates Coverage On Qiagen with Overweight Rating, Announces Price Target of $55

Morgan Stanley analyst Andrew Percoco maintains GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with a Overweight and raises the price target from $422 to $511.

Morgan Stanley Maintains Overweight on GE Vernova, Raises Price Target to $511

나스닥-100은 기술주가 끊임없는 상승을 이어가면서 화요일 사상 최고치인 22,191.37까지 급등했다. 이 지수를 추적하는 가장 인기 있는 ETF인 Invesco QQQ Trust(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)도 광범위한 기술 모멘텀을 반영하여 52주 최고가인 540달러를 경신했다.



<h2 class="wp-block-heading">메타의 거침없는 행진</h2>



메타 플랫폼스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)는 지난 금요일까지 20회 연속 거래 세션에서 높은 마감을 기록하며 절대적인 강세를 보였다. 화요일 개장 초에 주가가 반등했지만 마감에는 2.76% 하락했다.



1월 16일 이후 메타의 주가는 16% 급등하며 나스닥 상승을 부채질했다. QQQ 및 기타 주요 ETF에서 메타의 적절한 비중을 고려할 때, 메타의 랠리는 기술주 중심의 나스닥과 더 넓은 시장을 모두 상승시키는 핵심 원동력이었다.



또한 읽기: <a href="https://www.benzinga.com/25/02/43726758/meta-platforms-could-break-winning-streak-missing-20th-day-of-gains-as-overbought-conditions-employee-layoffs-dampen-sentiment" target="_blank" rel="noreferrer noopener">마크 저커법그의 메타 주식은 과매수 조건으로 인해 19일 연승 행진을 이어갈 예정이며, 직원 해고는 분위기를 약화시킨다</a>



<h2 class="wp-block-heading">AI, 실적, 경제적 탄력성</h2>



인공지능(AI) 붐은 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), 마이크로소프트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) 및 알파벳(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)가 주도하는 등 계속해서 지배적인 주제이다.



분석가의 기대를 뛰어넘는 기술 부문의 기업들의 <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">강력한 기업 실적</a>도 중추적인 역할을 했다.



한편, 소비자 지출 및 GDP 성장과 같은 경제 지표는 투자자 신뢰를 위한 견고한 기반을 제공하고 있다.



다음 읽기: <a href="https://www.benzinga.com/government/regulations/25/02/43711974/trump-launches-plan-for-reciprocal-tariffs-sp-500-nears-record-highs-dollar-tumbles-as-investors-cheer-on-late-kickoff" target="_blank" rel="noreferrer noopener">트럼프, &#8216;상호 관세&#8217; 계획 개시: S&amp;P 500이 사상 최고치에 가까워지고 달러 폭락</a>



<h2 class="wp-block-heading">연준 요인</h2>



투자자들은 연방준비제도(연준)가 금리 인상 주기의 정점에 도달했다고 추측하고 있다. 낮은 금리는 나스닥-100의 상승 모멘텀을 더욱 촉진하여 성장주를 더욱 매력적으로 만들 것이다.



인플레이션은 완화될 조짐을 보여 연준이 좀 더 비둘기파적이라면 주식 가치 평가가 더 높아질 수 있다는 낙관론을 불러일으킨다.



<h2 class="wp-block-heading">더 많은 상승 여력을 지닌 기술적 돌파?</h2>



LPL 파이낸셜의 최고 기술 전략가인 아담 턴퀴스트(Adam Turnquist)에 따르면 나스닥-100은 12월 최고치를 확실히 돌파했으며 더 많은 상승 여지가 있을 수 있다고 한다.



턴퀴스트는 &#8220;최소 기술 기반 가격 목표는 23,650 근처로 설정되었다&#8221;라고 말한다.



또한 S&amp;P 500 대비 상대적인 강세가 개선되고 있어 나스닥의 리더십이 계속되고 있음을 나타낸다.



<h2 class="wp-block-heading">급등에 편승하는 ETF 승자들</h2>



기술주 중심 ETF가 랠리의 혜택을 누리고 있다. Invesco QQQM(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQM#NASDAQ">QQQM</a>)과 First Trust Nasdaq BuyWrite Income ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTQI#NASDAQ">FTQI</a>)는 꾸준한 상승세를 보였으며, 더 넓은 속도이긴 하지만 SPDR S&amp;P 500 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)도 상승했다.



기술주가 선두를 달리고 있고 메타의 끊임없는 랠리가 모멘텀을 유지하면서 나스닥-100은 더욱 기록적인 움직임을 보일 것으로 보인다.







다음 읽기:



<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/02/43737344/sp-500-nears-another-all-time-high-whats-driving-the-action" target="_blank" rel="noreferrer noopener">S&amp;P 500이 또 다른 사상 최고치에 가까워졌다: 요인은?</a></li>
</ul>



Photo: Shutterstock



Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

금요일 Arm 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>)의 주가는 엑산 BNP 파리바(Exane BNP Paribas)가 주식을 <a href="https://www.benzinga.com/news/24/04/38299189/whats-going-on-with-arm-holdings-stock">시장수익률 상회(Outperform)에서 중립(Neutral)</a>으로 하향 조정한 후 금요일 급락했다.
상세 정보:
엑산 BNP 파리바의 분석가 데이비드 오코너(David O&#8217;Connor)는 Arm을 시장수익률 상회(Outperform)에서 중립(Neutral)으로 <a href="https://www.benzinga.com/quote/ARM/analyst-ratings">하향 조정</a>하고 주가 목표를 100달러로 발표했다.
ASML 홀딩스 N.V.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>)와 대만 반도체(TSMC)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>)의 실적이 <a href="https://www.benzinga.com/markets/equities/24/04/38328610/tsmc-cautions-red-hot-chip-industry-growth-could-cool-amid-declining-automotive-chip-demand">반도체 부문</a>에 압박을 가하면서 Arm 주가는 지난 5일 동안 30% 이상 하락했다.
ASML은 예상보다 저조한 1분기 실적을 기록했고, TSMC는 회사의 1분기 실적을 무색하게 만드는 소비자 약세가 지속되는 것을 보고 칩 시장에 대한 전망을 낮췄다.
1분기 실적 시즌이 본격화되면서 투자자들이 최신 데이터와 매출 감소 가능성을 고려하면서 반도체 기업 주가가 하락하고 있다. 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)의 주가는 10% 하락했으며 슈퍼 마이크로 컴퓨터 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)의 주가는 금요일 23% 이상 하락 마감했다.
SMCI는 3분기 실적을 발표했지만 이전 분기와 마찬가지로 예비 추정치를 제공하지는 않았다. 투자자들은 예비 추정치가 없기 때문에 이 회사의 실적이 더 낮을 수 있다고 추측할 수 있다.
투자자는 Arm을 보유 자산으로 포함하는 First Trust Nasdaq BuyWrite Income ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTQI#NASDAQ">FTQI</a>) 또는 iShares Robotics and Artificial Intelligence Multisector ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRBO#NYSE">IRBO</a>)의 주식을 구매하여 Arm에 대한 노출을 얻을 수 있다.
관련 뉴스 <a href="https://www.benzinga.com/news/24/04/38341107/whats-going-on-with-nvidias-stock">엔비디아의 주가에 무슨 일이 일어나고 있는 것일까?</a>
ARM 주가 움직임: <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>에 따르면 금요일 Arm 홀딩스의 주식은 16.90% 급락한 87.19달러로 마감했다. 이번 주는 31.08% 빠졌다.
이미지:wikimedia commons

Comments

First Trust Nasdaq BuyWrite Income ETF

뉴스

에 대한 최신 뉴스 First Trust Nasdaq BuyWrite Income ETF (NASDAQ:FTQI)

수요일, 2월 19, 2025

토요일, 4월 20, 2024

뉴스

파트너 / 기고자

벤징가 글로벌